All phar­ma com­pa­nies in the first round of Medicare price ne­go­ti­a­tions agree to par­tic­i­pate

All com­pa­nies with drugs on CMS’ list for the first round of Medicare price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act have agreed to par­tic­i­pate as of this morn­ing, the dead­line by which com­pa­nies had to sub­mit new drug da­ta to CMS.

John­son & John­son, Am­gen and No­var­tis have all signed ne­go­ti­a­tion agree­ments ahead of the Oct. 1 dead­line, they told End­points News on Mon­day. No­vo Nordisk al­so agreed to par­tic­i­pate, End­points learned on Sun­day. Mer­ck, Boehringer In­gel­heim, Bris­tol My­ers Squibb and As­traZeneca pre­vi­ous­ly an­nounced their in­ten­tions to agree to the ne­go­ti­a­tions. Com­pa­nies that do not com­ply would face a heavy tax or risk los­ing out on Medicare and Med­ic­aid cov­er­age al­to­geth­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.